stock
None
NASDAQ:ALT
12.68
+0.45 (+3.68%)
As of 2022-09-28, 09:50 AM (EST)
52 Week Rng -
Market Cap -
Avg Volume -
1M Volatility -
Short Ratio -
P/E Ratio (TTM) -
P/E Ratio (Fwd) -
P/B Ratio -
Div & Yield -
BUY
5
×
ACTION
TICKER
SHARES
STATUS
[SELL]
250
Filled
ACTION
TICKER
SHARES
STATUS
SELL
40
Filled
ACTION
TICKER
SHARES
STATUS
[SELL]
1,500
Filled
ACTION
TICKER
SHARES
STATUS
BUY
100
×
ACTION
TICKER
SHARES
STATUS
SELL
149
Filled
ACTION
TICKER
SHARES
STATUS

leoleppaaho Aalto Investment Management Game (Fall 2020) Dec 2020

Passive buy-and-hold strategy based on momentum and diversification | Long position: 10 companies with the highest YTD-earnings from 3 different sectors + 1 ETF with the highest YTD-earnings in its sector | equally weighted between the four sectors | adjusting weights 12/02/20

SELL
149
×
ACTION
TICKER
SHARES
STATUS

leoleppaaho Stockfuse Continuum (US) Dec 2020

Passive buy-and-hold strategy based on momentum and diversification | Long position: 10 companies with the highest YTD-earnings from 3 different sectors + 1 ETF with the highest YTD-earnings in its sector | equally weighted between the four sectors | adjusting weights 12/02/20

BUY
5,108
Filled
ACTION
TICKER
SHARES
STATUS

AIJOFund Aalto Investment Management Game (Fall 2020) Nov 2020

Momentum strategy | Equal weighting | Long position: 30 stocks with highest cumulative returns during the last 12 months | Rank 10

*Includes only companies available in the game

[SELL]
9,000
Filled
ACTION
TICKER
SHARES
STATUS
BUY
100
×
ACTION
TICKER
SHARES
STATUS
BUY
5,000
×
ACTION
TICKER
SHARES
STATUS
[BUY]
3,255
Filled
ACTION
TICKER
SHARES
STATUS

lord_mack21 Long Term Value Investment Challenge Jul 2020

Automatic trade executed by Stockfuse to ensure margin compliance.

[BUY]
4,000,000
Filled
ACTION
TICKER
SHARES
STATUS
[SELL]
40
Filled
ACTION
TICKER
SHARES
STATUS
[BUY]
25,000
Filled
ACTION
TICKER
SHARES
STATUS
[BUY]
11,000,000
Filled
ACTION
TICKER
SHARES
STATUS
BUY
1,000
×
ACTION
TICKER
SHARES
STATUS
BUY
100
×
ACTION
TICKER
SHARES
STATUS

RehanShah Stockfuse Continuum (US) Jul 2020

Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease and immune modulating therapies. Our diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX™ and NasoShield™). Altimmune Announces Dosing of First Patient in Phase 1b Clinical Trial of NasoShield™, a Single Dose Intranasal Anthrax Vaccine Candidate. Altimmune Receives Award from U.S. Department of Defense to Fund Phase 1/2 Clinical Trial of T-COVID™ in Outpatients with Early COVID-19. Altimmune Announces IND Clearance for a Phase 2 Trial of HepTcell™ Immunotherapeutic for the Treatment of Chronic Hepatitis B. Altimmune’s Largest Investor Sees Potential Coronavirus Vaccine, Buys More Stock.

BUY
20
×
ACTION
TICKER
SHARES
STATUS
BUY
1,000
Filled
ACTION
TICKER
SHARES
STATUS
more
AAPL TSLA OPK AMZN GLPG TNK EXAS PACB STKL GST
Market data provided by Xignite, BATS BZX Real-Time Price, and SIX Financial Information.